Table 1.
Indicators of quality of care that climacteric stage women receive in family medicine clinics
| Indicator | Formula |
|---|---|
| I. Health promotion | |
| 1. Counseling about climacteric stage and menopause in the last year | Number of climacteric stage women who received counseling about climacteric stage, menopause and self-care related activities by the family doctor or other health professionals, in the last year/Total number of women in the sample × 100 |
| 2. Nutritional counseling in the last year | Number of climacteric stage women who received nutritional counseling by the family doctor or other health professionals, in the last year/Total number of women in the sample × 100 |
| 3. Advice on regular leisure time physical activity in the last year | Number of climacteric stage women who received advice on regular leisure time physical activity by the family doctor or other health professionals, in the last year/Total number of women in the sample × 100 |
| 4. Smoke cessation counseling in the last year | Number of current smokers climacteric stage women who received smoke cessation counseling by the family doctor or other health professionals, in the last year/Total number of actively smoking women in the sample × 100 |
| II. Screening | |
| 1. Deliberate search of climacteric symptoms in the last year | Number of climacteric stage women who were asked by the family doctor about climacteric symptoms in the last year/Total number of women in the sample × 100 |
| 2. Screening for overweight and obesity by calculating the body mass index (BMI) in the last year | Number of climacteric stage women who received overweight and obesity screening through the BMI calculation by the family doctor in the last year/Total number of women in the sample × 100 |
| 3. Screening for hypertension by measuring the systolic and diastolic blood pressure in the last year | Number of climacteric stage women that received hypertension screening through measuring the systolic and diastolic blood pressure by the family doctor or other health professionals, in the last year/Total number of women in the sample × 100 |
| 4. Screening for diabetes by measuring fasting plasma glucose in the last year | Number of climacteric stage women who received diabetes screening through fasting plasma glucose measurement, in the last year/Total number of women in the sample × 100 |
| 5. Screening for breast cancer through mammography in the last 2 years | Number of climacteric stage women who received breast cancer screening through mammography, in the last 2 years/Total number of women in the sample × 100 |
| 6. Screening for cervical cancer through Pap test in the last 3 years in women without a history of total hysterectomy | Number of climacteric stage women without a history of total hysterectomy for benign disease who received cervical cancer screening through Pap test, in the last 3 years/Total number of women in the sample without a history of total hysterectomy × 100 |
| III. Treatment | |
| 1. Appropriate indication of oral hormone therapy (HT) | a) Number of women with moderate or severe vasomotor symptoms 7/day ≥ (at the time of the interview or the time to start oral HT) and without HT contraindications, who receive oral HT |
| b) Number of women with moderate or severe vasomotor symptoms <7/day(at the time of the interview or the time to start oral HT), or with mild symptoms or without vasomotor symptoms who do not receive oral HT/Total number of women in the sample × 100 | |
| 2. Appropriate indication of vaginal HT | a) Number of women with moderate or severe vaginal atrophy symptoms and without oral HT who receive vaginal HT |
| b) the number of women without moderate to severe vaginal atrophy symptoms or with oral HT who do not receive vaginal HT/Total number of women in the sample × 100 | |
| 3. Appropriate prescription of oral HT | Number of women receiving oral HT prescription appropriately according to the drug scheme, dose, schedule and duration of the treatment/Total number of women in the sample receiving oral HT × 100 |
| 4. Information on risks and benefits of oral HT | Number of women who were prescribed oral HT and who received information about its purpose, benefits and risks/Total number of women in the sample receiving oral HT × 100 |